Iovance Biotherapeutics, Inc. Stock News

The FDA grants priority review to Iovance's (IOVA) filing seeking approval for its lead pipeline candidate in melanoma indication. A decision is expected before November-end.

Iovance (IOVA) reports Q1 earnings that beat our estimates. The company's acquisition of IL-2 product Proleukin is expected to close in second-quarter 2023.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Sara Pellegrino – Senior Vice President, Investor Relations and Corporate Co

SAN CARLOS, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report

SAN CARLOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno

Iovance Progresses Despite Challenges In Developing Potency Assays For Lifileucel.

Growth stocks fell across the board in 2022. This broad pullback may have created some tremendous buying opportunities.

Iovance Biotherapeutics: Looking Towards Successful FDA Review In 2023

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock?

Iovance is looking for approval for a metastatic melanoma therapy. Company CEO Frederick Vogt said it would be the first individualized, one-time cell therapy for a solid tumor.

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Biotech cancer-treatment developer Iovance Biotherapeutics Inc. IOVA, -3.83% on Friday said it had completed its rolling biologics license application submission to the U.S. Food and Drug Administrati

Iovance (IOVA) reports Q4 earnings in line with our estimates. Management is on track to complete the rolling BLA submission for lifileucel in melanoma before first-quarter 2023 ends.

SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Sara Pellegrino - Senior Vice President, Investor Relations and Corporat